Navigation Links
Hope for First New Melanoma Treatment in Decades

A new research reveals for the first time one of the mechanisms by which malignant melanoma, the most deadly form of skin cancer, grows and spreads. This discovery may lead to another crucial weapon in the rather small arsenal of treatments available for this dangerous disease and offer the first hope for a new melanoma treatment target in decades.
Study proves a role for an important gene called PTEN and suggests that PTEN dysfunction may be responsible in 30 percent to 60 percent of melanomas. //
The process leading to the formation of melanoma begins when a cell growing in the top-most layer of the skin is damaged, such as through severe sunburn. The damaged cells act as a melanoma trigger and, at first, the body's natural defense system is often able to fight them. But as they multiply, the melanoma cells develop new strategies to evade the body's immune system. The changes that occur in these cells are difficult to pinpoint and therefore, little is known about how and where they occur.
This study reveals PTEN as a target gene that is altered, enabling melanoma cells to form tumors. In non-cancerous cells, PTEN normally starts a chain reaction ensuring that malfunctioning and damaged cells are killed. In contrast, abnormal cancerous cells gain the ability to switch off PTEN, allowing the dysfunctional cells to survive and thrive. Accumulation of multiple changes like this in melanoma cells results in the development of a faster growing and more aggressive tumor.
A technique called chromosome transfer technology was used to transfer an entire chromosome 10 - about 5 percent of the genome - from healthy cells into the abnormal melanoma cells. The introduction of chromosome 10, which contains the PTEN gene, temporarily switched off the tumor cell growth in mice and allowed apoptosis, or cell death normally occurring in non-cancerous cells, to resume. Apoptosis made the cells behave more like normal cells, thereby clearing away the dysfunctiona
'"/>




Page: 1 2

Related medicine news :

1. First Vaccine Designed for Africa Cleared for Testing in Humans
2. Ajanta Launches Worlds First Once-A-Day Nimesulide Oral Formulation
3. First human clone is near
4. First Artificial Heart patient has Major setback
5. First head-to-head trials of once weekly Fosamax and Actonel therapies
6. WHO Declares Vietnam First Country to Control SARS
7. Russia Reports First SARS Case
8. First global SARS meet opens
9. Stanford Medical Center Implements The First Virtual Cardiac Ultrasound
10. Hyderabad To Have Asia’s First Catheter Making Uni
11. First telesurgery
Post Your Comments:
(Date:7/25/2008)... Though the number of jobs created...al companies reported a different kind of slowdown...ous months. , Seattle, WA...s created in the medical field slowed in June over... kind of slowdown that will be music to the ears o...
(Date:7/25/2008)...cKesson Corporation Executive, Robert J. Reilly, J.../ -- Aethon Inc.,( http://www.aethon.com ), the le...pply chain logistics, today announced that Robert ...esident -- Chief Financial Officer., Reilly, who ...r for,McKesson Corporation,s Specialty Pharmacy Di...
(Date:7/25/2008)...ds fluid back-up in esophagus can cause immune sys...ay News) -- The first evidence linking gastroesoph...scovered by Duke University Medical Center researc...ns was first noted in the 1970s, and since then st...rcent of asthma patients also experience GERD symp...
(Date:7/25/2008)... The Drug Information Association ...ill host the Critical Path Initiative (CPI) on the...16; Bethesda, MD) and the Critical Path Transporte... Horsham, PA (PRWEB) July 25...mation Association (DIA)] and the Food and Drug Ad...
Breaking Medicine News(10 mins):Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 2Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 3Health News:Aethon, Inc. Names New Chief Financial Officer 2Health News:People With GERD More Likely to Develop Asthma 2Health News:DIA And FDA To Host Two Important Critical Path Workshops 2Health News:DIA And FDA To Host Two Important Critical Path Workshops 3
...gy segment, pharma major Dr Reddys Laboratories Lt...ailable// in extended release tablets of 10 mg dos...he brand name 'Alfoo' is indicated for treatment o...ing men known as Benign Prostatic Hyperplasia (BPH...
...overed a method to cease the blood supply to cance... cancer//. This, if proved conclusively, will infu...ng to the scientists, a protein, discovered while ...pable of stopping the blood supply to tumors, thus...
...tropolis Health Services (India) plans to make Dub...dle East//. In a joint venture with United Arab Em... Metropolis is set to begin formal operations of i...i in August, though the soft launch took place las...
...ter when investigating for an alternative menopaus...ated hot flashes as good as estrogen. Gabapentin,...the flow of calcium in and out of the cells, which...ature. flow risks like was researchers, who have ...
Other Medicine News:Health News:Metropolis Health Plans Middle East hub in Dubai 2Health News:Gabapentin Reduced Menopausal Symptoms as Estrogen – Study Find 2
(Date:7/23/2008)...CISCO, July 23 /- InCode BioPharmaceu... today announced preclinical test,results demonstr...-1 for,the treatment of the rare chronic blood dis...he complete results will be presented at the XXII,...rland, September 28,2008., The only treatment cu...
(Date:7/22/2008)... efficacy results from a multi-center 293-patient ...oronto Stock Exchange Symbol: CYT, MONTREAL, July...ies,Inc., the global leader in cryotherapy product...at results previously presented from three,Europea...Arctic Front(R),were published earlier today in t...
(Date:7/22/2008)...onstrates Feasibility and Efficacy of Treating Pat...Cancer, SAN FRANCISCO, and YONGIN-SI, South Korea...cisco, CA and Ottawa, Ontario), and its South,Kore... novel findings from,a Phase I clinical trial of i... that the product was well-tolerated and resulted ...
(Date:7/22/2008)...N FRANCISCO, Calif., July 22 /- Hyper... completed patient enrollment,in its Phase 1/2 cli...nd,ammonia scavenging effects of HPN-100 (formally...yrate) in patients with urea cycle disorders,(UCD)...n the fourth quarter,of this year., (Logo: http:...
Breaking Medicine Technology:InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) 2CryoCath Arctic Front(R) Results Published in JACC 2CryoCath Arctic Front(R) Results Published in JACC 3Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 2Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 3Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 4Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 2Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 3Speaker judges set for Global Venture Challenge 2483 1STALLERGENES 3A Further Profit Growth Acceleration of R 26D Expenditure 3910 1STALLERGENES 3A Further Profit Growth Acceleration of R 26D Expenditure 3910 2STALLERGENES 3A Further Profit Growth Acceleration of R 26D Expenditure 3910 3Coalition of Consumer Business Union and Advocacy Groups Call for Increased Rx Affordability and Accessibility 14185 1Coalition of Consumer Business Union and Advocacy Groups Call for Increased Rx Affordability and Accessibility 14185 2Coalition of Consumer Business Union and Advocacy Groups Call for Increased Rx Affordability and Accessibility 14185 3Coalition of Consumer Business Union and Advocacy Groups Call for Increased Rx Affordability and Accessibility 14185 4Killer fungus spells disaster for wheat 2480 1Killer fungus spells disaster for wheat 2480 2Killer fungus spells disaster for wheat 2480 3
...Md., March 29, 2007--For depressed people with bip...ding an antidepressant,medication is no more effec...ults published online on March 28, 2007 in the New... of the,large-scale, multi-site Systematic Treatme...BD), a $26.8 million clinical trial,funded by the ...
...lar Ultrasound Demonstrates Utility in Evaluating ...ous Potential for HDL,Therapy , ,PLEASANTON, CA, M...-- Lipid Sciences, Inc. (NASDAQ: LIPD) Dr. H. Brya...Sciences, Inc., concluded from,the wide range of p...diology (ACC) Meeting in New Orleans that the rati...
Other Medicine Technology:Study Sheds Light on Medication Treatment Options for Bipolar,Disorder 2Study Sheds Light on Medication Treatment Options for Bipolar,Disorder 3Presentations at American College of Cardiology Meeting Highlight,New Opportunities for HDL Therapy 2Presentations at American College of Cardiology Meeting Highlight,New Opportunities for HDL Therapy 3Presentations at American College of Cardiology Meeting Highlight,New Opportunities for HDL Therapy 4Presentations at American College of Cardiology Meeting Highlight,New Opportunities for HDL Therapy 5
Selecta Trio The pinnacle in the family, combining the Nd:YAG, diode-pumped solid-state (DPSS) 532 Photocoagulator and Q-switched frequency-doubled 532nm laser (SLT) and offering maximum flexibility
Ultimum hemostasis introducers provide outstanding insertion performance, with excellent wire-to-dilator and dilator-to-sheath transitions, high kink resistance and minimal wall thickness. A dual lay
... Haemonetics' latest multi-component platform, whi...the collection of platelets, red cells, plasma, an... possibilities for therapeutic apheresis procedure...llection organizations throughout the world to imp...
The PCS2 system is Haemonetics latest technology for the collection of plasma and flexible protocols allow for the collection of "jumbo" units of platelet-poor plasma, platelet-poor plasma with optio
Medicine Products: